The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Acquired | Acquired

Total Raised




About GANYMED Pharmaceuticals

Ganymed Pharmaceuticals is a biopharmaceutical company that researches, develops, and produces pharmaceutical products and therapeutic drugs for the treatment of solid cancers. It focuses on developing ideal monoclonal antibodies (IMABs) that include cancer-selective targets for maximal high-precision anticancer potency, as well as mitigates the threat of toxicity. The company's pipeline includes IMAB362, IMAB027, GT468, and GT352 and GT353 cell-surface molecules. It also develops Claudetect18.2, a CE marked in vitro diagnostic test to assess the expression levels of claudin-18.2 in gastroesophageal, pancreatic, lung, and other solid tumors.

GANYMED Pharmaceuticals Headquarter Location

An der Goldgrube 12

Mainz, D-55131,


+49 (0) 6131 / 1440-100

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing GANYMED Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

GANYMED Pharmaceuticals is included in 2 Expert Collections, including Cancer.



4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

GANYMED Pharmaceuticals Patents

GANYMED Pharmaceuticals has filed 76 patents.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Experimental cancer drugs
  • Transcription factors
patents chart

Application Date

Grant Date


Related Topics




Monoclonal antibodies, Experimental cancer drugs, Transcription factors, Clusters of differentiation, Oncology


Application Date


Grant Date



Related Topics

Monoclonal antibodies, Experimental cancer drugs, Transcription factors, Clusters of differentiation, Oncology



Latest GANYMED Pharmaceuticals News

BioNTech founders Ugur Sahin and Özlem Türeci are honored with the Axel Springer Award

Mar 18, 2021

The Corona vaccine developed by the medical couple Ugur Sahin and Özlem Türeci was the first approved worldwide. For this, they will be presented with the Axel Springer Award this Thursday evening - which you can follow live via our stream from 7 p.m. here. The Federal Cross of Merit will follow on Friday: German President Frank-Walter Steinmeier will present it at Bellevue Palace in the presence of German Chancellor Angela Merkel. This is an automated machine translation of an article published by Business Insider in a different language. Machine translations can generate errors or inaccuracies; we will continue the work to improve these translations. You can find the original version here . By now, everyone has probably heard their names. Medical couple Ugur Sahin and Özlem Türeci, completely unknown to most before the Corona pandemic began, have become heroes of the crisis: Their mRNA vaccine Comirnaty was the first to be regularly licensed worldwide against the coronavirus. For this, they will be presented with the Axel Springer Award this Thursday evening - which you can follow live via our stream from 7 p.m. here. It will not remain the only award that the two rather publicity-shy researchers will receive. The Federal Cross of Merit will follow on Friday: Federal President Frank-Walter Steinmeier will present it at Bellevue Palace in the presence of Chancellor Angela Merkel. The Nobel Prize may even be on the horizon - many would at least like to see them get it. Three elements led to success, say Sahin and Türeci The medical experts revealed to Business Insider what he sees as the three elements that were crucial to the vaccine development project, dubbed "Lightspeed," actually moving so quickly. The first, he said, was the combination of technology and science. "Because of our decades of research on mRNA technologies in individual cancer medicine, we had both the knowledge and the technology to develop custom mRNA vaccines in a matter of weeks," Sahin says. "We had done this hundreds of times before. So, as immunologists, we were able to precisely define how the mRNA vaccine should target the immune system against the virus." The second element, he says, was a willingness to take risks. "We had made a joint decision in the executive and supervisory boards to refocus our research and invest significant resources in the project," Sahin said. "There was no guarantee of success - but we wanted to leave no stone unturned. We knew we could make a difference and felt we had a duty to help if we could." The third element, he says, was the great determination of everyone involved in making it happen. Sahin recounts, "With "Project Lightspeed," we relentlessly followed the principle of minimizing development times without skipping development steps or taking shortcuts. In doing so, we trusted in the capabilities of our outstanding team and that science would guide us." Thus, he said, tasks that are normally approached sequentially in vaccine development were done in parallel. The teams worked tirelessly, in self-coordinated 24/7 shifts. "Another important element was collaborations: Everyone pulled together. Our partnerships with Pfizer, Fosun, and other companies increased international reach via complementary expertise." Early dialogue with regulatory agencies and governments was also an important cornerstone of the vaccine's rapid approval, he said. "Our whole mantra was: we have no time to lose, because every day and every hour counts," Sahin says. It wasn't until they reached their goal, he says, that they themselves realized that this was by far the fastest vaccine development in the history of medicine. From guest worker children to cancer researchers - and billionaires For 20 years, the pair worked on mRNA technology; together they published hundreds of scientific papers and filed countless patents. Only now is all that work paying off. In early October, Welt am Sonntag published a list of the richest people in Germany. In 93rd place: medicine professor Ugur Sahin and his wife Özlem Türeci. Their fortune has risen from 650 million to 2.4 billion euros within a year - in other words, it has almost quadrupled in such a short time. But who are the two scientists behind the vaccine? Sahin's family came to Germany from Turkey when he was four years old. His father worked as a guest worker at Ford. Sahin first studied medicine in Cologne, and later worked in internal medicine and hematology/oncology at the University Hospital in Cologne. He wrote his doctoral thesis on immunotherapy in tumor cells. Since then, his focus has been on cancer research and immunology. Since 2006, Sahin has been Professor of Experimental Oncology at the III Medical Clinic of the University of Mainz. Özlem Türeci also has Turkish roots: Her father, a doctor, had come to Germany from Istanbul to work in a hospital here. Like him, Türeci studied medicine and became a doctor. " Heise" reports that she and Sahin met in the early 1990s in the cancer ward of the hospital in Homburg an der Saar. Both were fascinated by the idea of being able to treat cancer in a way other than surgery, chemotherapy, and radiation. They wanted to get the immune system to attack the cancer cells themselves - and they succeeded. Together, they founded Ganymed Pharmaceuticals in 2001: The biopharmaceutical company specialized in antibody drugs against tumors. "Sahin never prioritized monetization". Fifteen years later, the couple sold Ganymed Pharmaceuticals to a Japanese pharmaceutical company - for about 422 million euros. However, the topic remained with them: Even today, private lecturer Özlem Türeci is considered a pioneer in the field of cancer immunotherapy and is a board member of the German top cluster for individualized immune intervention Ci3. But this company is not the only one the couple founds. In 2008, they set up BioNTech , another company researching medical agents - and now, together with U.S. partner Pfizer, they were the first to have an approved Corona vaccine. Both companies launched a global test on the potential vaccine in late July 2020. No wonder, then, that Sahin and Türeci are among the most successful Germans. It doesn't seem to be about the money for the couple, however. Investor Thomas Strüngmann explained in an interview with Handelsblatt , "Sahin has never put monetization first." His dream, he said, is to "build something sustainable, lasting, and fundamentally develop new, better therapies." Disclaimer: Business Insider is a subsidiary of Axel Springer SE.

You May Also Like


Proacta is a clinical-stage, biopharmaceutical company focused on addressing unmet needs in the field of cancer with current efforts directed towards the development of hypoxia-activated prodrugs that target treatment-resistant cancer cells.


Onyvax is developing new cancer therapies that harness the selective power of the immune system to seek out and destroy tumor cells. Onyvax's products specifically target cancer cells, increasing the likelihood that they will be effective while minimising side effects associated with many conventional treatments. These therapies can broadly be classed as therapeutic cancer vaccines. Onyvax's lead product is in clinical trials for the treatment of prostate cancer and is poised to enter the final stages of development. Onyvax is committed to the commercialisation of therapies that enhance survival while maintaining a high quality of life for patients. The Company is based in London and has collaborations with leading hospitals and other institutions throughout Europe and the US.

Marillion Pharmaceuticals

Marillion Pharmaceuticals, Inc. - Marillion is developing clinical-stage drugs in oncology and oncology supportive care. 177Lu-AMBA is a targeted radiotherapeutic, with the low level radiation of lutetium that aims to utilize an receptor-based technology, and can serve as both a diagnostic and therapeutic agent. The targeting capability means that 177Lu-AMBA homes in on tumor cells and spares normal tissues. 177Lu-AMBA is being pursued initially to treat hormone-resistant prostate cancer, has been studied in a phase I trial in Europe. Marillion also is developing PilobucTM , buccal formulation of pilocarpine ,for the treatment of dry mouth, shown in clinical trials to effectively and conveniently deliver the drug with reduced side effects compared to other routes of administration.PilobucTM buccal formulation of pilocarpine has the potential to be a product in the xerostomia market. Marillion is preparing for phase II trials of the product candidate..

Femta Pharmaceuticals

Femta is developing a new generation of antibody therapeutics for major disease indications.


Evogenix aims to provide advanced technologies to provide powerful new antibody therapeutics for world markets.

Oncology Research Therapeutics

Oncology Research Therapeutics, Inc. is dedicated to providing and discovering cancer diagnostics that improve the lives of patients suffering from a wide array of cancers. They also provide R&D services that improve drug development for the Biotech and Pharmaceutical industries.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.